Our Favorite Resources for Breast

• A nonprofit website dedicated to providing the most reliable and complete information available.
  Breastcancer.org

• Provides educational materials, events, newsletters, a Young Survivors Network, and a toll-free helpline at 800-753-5222.
  Living Beyond Breast Cancer

• A comprehensive site that offers a toll-free helpline (1-800-I'M AWARE), educational materials, advocacy, and fundraising events.
  Susan G. Komen for the Cure

More Resources

Updated results from the STAR P-2 trial, which compared the long-term effect of tamoxifen to Evista (raloxifene) in nearly 20,000 postmenopausal women, confirmed that both drugs significantly reduce the risk of breast cancer. However, tamoxifen had a more lasting effect but higher risk of side effects. 

Initial results from the trial, announced in 2006, found that both Evista and tamoxifen lowered the risk of invasive cancer equally, by about half after four years of follow-up. Evista, however, had fewer side effects, including uterine cancer and blood clots. Initially approved to prevent and treat osteoporosis, Evista was later approved for breast cancer prevention in 2007. 

Announced at the American Association for Cancer Research annual meeting in April, the latest results demonstrated that while the efficacy of Evista dipped slightly compared to tamoxifen once women stopped taking the drug, it is still a viable option for postmenopausal women at high risk for breast cancer, as is tamoxifen. At a median follow-up of seven years, it was estimated that Evista lowered the risk by 38 percent, while tamoxifen continued to decrease the risk by half.

Both drugs are relatively inexpensive with modest side effects, but only about 5 to 20 percent of high-risk women use them to reduce their risk of breast cancer, said Gabriel Hortobagyi, MD, chair of breast medical oncology at M.D. Anderson Cancer Center in Houston, at a press briefing during the meeting. Experts hope that because women and their physicians are familiar with Evista, it may be a more palatable option because a large population has been using it long-term for osteoporosis management. 

^ TOP OF PAGE